Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 20-23 , January 2004

Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin)

  • Xiaowei Zhu

      Affiliations

    • Department of Radiology, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
    • *Address reprint requests to Xiaowei Zhu, MS, DABMP, Department of Radiology, The Children’s Hospital of Philadelphia, 34th St and Civic Center Blvd, Philadelphia, PA 19104-4399, USA
    • 1Ms Zhu has received research grant support from Biogen Idec Inc.

References 

  1. Zevalin (ibritumomab tiuxetan) prescribing information. San Diego, CA: IDEC Pharmaceuticals Corporation,; 2002;
  2. Siegel JA, Zimmerman BE, Kodimer K, et al.  A single dose calibrator dial setting accurately measures 90Y ibritumomab tiuxetan activity. J Nucl Med. 2003;44:317P; abstr 1137)
  3. Bexxar (tositumomab and iodine 131 tositumomab) prescribing information. Seattle, WA: Corixa Corporation,; 2003;
  4. Kuzel TM, Rosen ST. Radioimmunotherapy of lymphomas and leukemias. In:  eds Henkin RE,  Boles MA,  Dillehay GL,  Halama A,  Zimmer M editor. Nuclear Medicine. St Louis, MO: Mosby-Year Book,; 1996;p. 584–600
  5. Wootton R. Radiation Protection of Patients. Cambridge: Cambridge University Press, England; 1993;
  6. Delacroix D, Guerre JP, Leblanc P, et al.  Radiation protection dosimetry. Radionuclide and Radiation Data Handbook. In: Ashford: Nuclear Technology Publishing, UK; 1998;p. 68; Nos. 1–2
  7. Zimmer M. Effectiveness of specific vial and syringe shields in reducing radiation exposure from 90Y Zevalin. J Nucl Med. 2002;43:45P; (abstr 164)
  8. Zanzonico PB, Binkert BL, Goldsmith SJ. Bremsstrahlung radiation exposure from pure β-ray emitters. J Nucl Med. 1999;40:1024–1028
  9. Wiseman G, Leigh B, Witzig T, et al.  Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med. 2001;28:1198; (abstr)
  10. Wiseman GA, Leigh BR, Erwin WD. Urinary clearance of 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin’s lymphoma. J Nucl Med. 2001;42:268P; abstr)
  11. Wiseman GA, White CA, Stabin M, et al.  Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med. 2000;27:766–777

PII: S0001-2998(03)00082-5

doi: 10.1053/j.semnuclmed.2003.11.005

Seminars in Nuclear Medicine
Volume 34, Issue 1, Supplement , Pages 20-23 , January 2004

Article Tools

* Image Usage & Resolution